# A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

> **NCT03748745** · PHASE1 · COMPLETED · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Drug Interactions

## Interventions

- **DRUG:** SH229
- **DRUG:** SH229
- **DRUG:** Daclatasvir dihydrochloride
- **DRUG:** Daclatasvir dihydrochloride

## Key facts

- **NCT ID:** NCT03748745
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-19
- **Primary completion:** 2018-12-25
- **Final completion:** 2018-12-25
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748745, "A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03748745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*